Journal article
Mammographic Density Phenotypes and Risk of Breast Cancer: A Meta-analysis
Andreas Pettersson, Rebecca E Graff, Giske Ursin, Isabel dos Santos Silva, Valerie McCormack, Laura Baglietto, Celine Vachon, Marije F Bakker, Graham G Giles, Kee Seng Chia, Kamila Czene, Louise Eriksson, Per Hall, Mikael Hartman, Ruth ML Warren, Greg Hislop, Anna M Chiarelli, John L Hopper, Kavitha Krishnan, Jingmei Li Show all
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE | OXFORD UNIV PRESS INC | Published : 2014
DOI: 10.1093/jnci/dju078
Abstract
BACKGROUND: Fibroglandular breast tissue appears dense on mammogram, whereas fat appears nondense. It is unclear whether absolute or percentage dense area more strongly predicts breast cancer risk and whether absolute nondense area is independently associated with risk. METHODS: We conducted a meta-analysis of 13 case-control studies providing results from logistic regressions for associations between one standard deviation (SD) increments in mammographic density phenotypes and breast cancer risk. We used random-effects models to calculate pooled odds ratios and 95% confidence intervals (CIs). All tests were two-sided with P less than .05 considered to be statistically significant. RESULTS: ..
View full abstractRelated Projects (3)
Grants
Awarded by National Cancer Institute at the National Institutes of Health
Awarded by Department of Defense grant DAMD
Awarded by National Institutes of Health
Awarded by Swedish Cancer Society
Awarded by SingHealth Foundation
Awarded by National Medical Research Council
Awarded by National University Cancer Institute, Singapore
Awarded by National Health and Medical Research Council
Awarded by Dutch Cancer Society
Awarded by Breast Cancer Campaign
Awarded by Cancer Research UK
Awarded by National Breast Cancer Foundation
Awarded by NATIONAL CANCER INSTITUTE
Funding Acknowledgements
This work was supported by the National Cancer Institute at the National Institutes of Health (R01 CA124865, R01 CA131332, P01 CA87969, R01 CA50385, R01 CA085265, R03 CA135699, R37 CA054281, R01 CA140286, R01 CA128931, R01 CA97396, P50 CA116201); Department of Defense grant DAMD 17-00-1-0331; the National Institutes of Health (R25 CA098566 to REG); the Marit and Hans Rausing's Initiative Against Breast Cancer; the W81XWH-05-1-0314 Innovator Award; the United States Department of Defense Breast Cancer Research Program; the Office of the Congressionally Directed Medical Research Programs; the Agency for Science, Technology and Research; the Swedish Cancer Society (5128-B07-01PAF to KC); the National Cancer Institute of Canada (to NFB); the SingHealth Foundation (SHF/FG450S/2009); the National Medical Research Council (NMRC/0711/2002); the National University Cancer Institute, Singapore (NMRC/CG/NCIS/2010); the MammoGrid Project (to RMLW); the Victorian Breast Cancer Consortium; the National Breast Cancer Foundation; the Cancer Council Victoria; the National Health and Medical Research Council (251533, 209057, 504711, 454671 to JS); the case-control study within the EPIC-NL cohort was funded by the Dutch Cancer Society (KWF 2008-4071 and KWF h1-4348); the EPIC-NL cohort was funded by the 'Europe against Cancer' program of the European Commission (SANCO); the Dutch Ministry of Health, Welfare and Sports (WVS) and ZonMW; Breast Cancer Campaign (2007MayPR23 to VM).